Merck & (MRK) Revenue — Quarter Ended Mar 31, 2024
Revenue for the reporting period increased compared with the prior quarter, continuing the upward trend observed over recent periods. On a year-over-year basis, revenue also grew relative to the same quarter last year.
Key takeaway
Quarter ended Mar 31, 2024 · FY2024 Q1
Revenue for the reporting period increased compared with the prior quarter, continuing the upward trend observed over recent periods. On a year-over-year basis, revenue also grew relative to the same quarter last year.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$15.8B
Revenue reported for this quarter.
Quarter-over-quarter
+7.8%
Change from the immediately preceding quarter.
Year-over-year
+8.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$61.4B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2023 | $15B | +3.0% |
| Sep 30, 2023 | $16B | +6.7% |
| Dec 31, 2023 | $14.6B | +5.8% |
| Mar 31, 2024 | $15.8B | +8.9% |
Revenue performance
Revenue rose sequentially, recovering from the decline seen in the previous quarter, and showed a positive year-over-year comparison. The company’s operating cash flow improved notably from the prior year, partly reflecting stronger operational performance.
Quarterly comparison
Compared with the immediately preceding quarter, revenue was higher, reversing the prior period’s decline. Versus the same quarter one year ago, revenue also increased, indicating sustained growth compared with the prior year.
What to watch
The company’s cash flow from operations strengthened significantly, though milestone and option payments reduced operating cash flow in both periods; ongoing liquidity and capital allocation remain key monitoring points.